

Sandra Vukusic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1119000/publications.pdf>

Version: 2024-02-01

68
papers

11,005
citations

159585

30
h-index

102487

66
g-index

69
all docs

69
docs citations

69
times ranked

9010
citing authors

#	ARTICLE	IF	CITATIONS
1	Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter. <i>Clinical Neuroradiology</i> , 2022, 32, 677-685.	1.9	3
2	Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1155-1159.	3.0	13
3	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsingâ€“Remitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.	4.4	5
4	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
5	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	7.2	30
6	COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 5571-5581.	3.6	4
7	Oral noregestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1458-1463.	3.0	8
8	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	1.1	24
9	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	5.3	123
10	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 378-386.	4.4	5
11	Cumulative effects of therapies on disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1760-1770.	3.0	11
12	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3
13	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.	3.3	8
14	MRI findings in blinded trials should be available to treating physicians â€“ Yes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 812-813.	3.0	1
15	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1543-1555.	3.0	33
16	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. <i>Neurology</i> , 2021, 97, e403-e413.	1.1	10
17	Update on brain MRI for the diagnosis and follow-up of MS patients. <i>Presse Medicale</i> , 2021, 50, 104067.	1.9	5
18	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.1	15

#	ARTICLE	IF	CITATIONS
19	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
20	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	5.9	8
21	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
22	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103164.	2.0	6
23	Post-partum relapse in women with multiple sclerosis after neuraxial labour analgesia or neuraxial anaesthesia: A multicentre retrospective cohort study. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100834.	1.4	5
24	Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset. <i>NeuroImage</i> , 2021, 244, 118589.	4.2	23
25	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2128271.	5.9	32
26	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 1001-1011.	10.2	36
27	Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. <i>Multiple Sclerosis Journal</i> , 2020, 26, 118-122.	3.0	69
28	Spontaneous multiple cervical artery dissections after alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2020, 26, 381-383.	3.0	14
29	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	3.0	37
30	Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 829-836.	3.0	39
31	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020, 77, 94.	9.0	36
32	Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	49
33	Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1680-1688.	1.9	0
34	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
35	Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852097822.	3.0	3
36	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	3.0	21

#	ARTICLE	IF	CITATIONS
37	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
38	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.	9.0	357
39	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor. Multiple Sclerosis Journal, 2020, 26, 1610-1611.	3.0	0
40	New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. Journal of Neuroradiology, 2020, 47, 250-258.	1.1	46
41	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology, 2019, 93, e635-e646.	1.1	36
42	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. Journal of Neurology, 2019, 266, 1743-1755.	3.6	9
43	Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Current Opinion in Neurology, 2019, 32, 459-466.	3.6	38
44	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.0	13
45	Efficacy of rituximab in refractory RRMS. Multiple Sclerosis Journal, 2019, 25, 828-836.	3.0	28
46	Cranial nerve involvement in patients with MOG antibody-associated disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e543.	6.0	53
47	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
48	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.1	401
49	Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure. Scientific Reports, 2018, 8, 13650.	3.3	171
50	Where there is inflammation, treatment may reduce disability progression – No. Multiple Sclerosis Journal, 2018, 24, 1810-1812.	3.0	1
51	Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?. European Journal of Radiology, 2018, 105, 204-208.	2.6	12
52	Unusual neurologic presentation of aseptic abscesses syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e469.	6.0	1
53	Multiple sclerosis broke my heart. Annals of Neurology, 2017, 81, 754-758.	5.3	22
54	MOG antibody-related disorders: common features and uncommon presentations. Journal of Neurology, 2017, 264, 1945-1955.	3.6	119

#	ARTICLE	IF	CITATIONS
55	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	3.0	89
56	Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey. <i>PLoS ONE</i> , 2017, 12, e0185104.	2.5	2
57	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1719-1731.	3.0	249
58	Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. <i>Annals of Neurology</i> , 2016, 80, 791-791.	5.3	1
59	Risk of relapse after natalizumab withdrawal. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e297.	6.0	34
60	Comparative efficacy of fingolimod vs natalizumab. <i>Neurology</i> , 2016, 86, 771-778.	1.1	71
61	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. <i>Neurology</i> , 2015, 85, 2076-2078.	1.1	28
62	Multiple sclerosis and pregnancy in the 'treatment era'. <i>Nature Reviews Neurology</i> , 2015, 11, 280-289.	10.1	99
63	Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 953-955.	3.0	35
64	Natural history of multiple sclerosis: a unifying concept. <i>Brain</i> , 2006, 129, 606-616.	7.6	736
65	Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 327-332.	1.4	97
66	Pregnancy and multiple sclerosis (the PRIMs study): clinical predictors of postpartum relapse. <i>Brain</i> , 2004, 127, 1353-1360.	7.6	573
67	Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. <i>Brain</i> , 2003, 126, 770-782.	7.6	839
68	Relapses and Progression of Disability in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2000, 343, 1430-1438.	27.0	1,135